Circadian disruption and cancer- and treatment-related symptoms

dc.contributor.authorAmidi, Ali
dc.contributor.authorWu, Lisa M.
dc.contributor.departmentDepartment of Psychology
dc.date.accessioned2026-10-09T10:15:01Z
dc.date.available2026-10-09T10:15:01Z
dc.date.issued2022-10
dc.description.abstractCancer patients experience a number of co-occurring side- and late-effects due to cancer and its treatment including fatigue, sleep difficulties, depressive symptoms, and cognitive impairment. These symptoms can impair quality of life and may persist long after treatment completion. Furthermore, they may exacerbate each other’s intensity and development over time. The co-occurrence and interdependent nature of these symptoms suggests a possible shared underlying mechanism. Thus far, hypothesized mechanisms that have been purported to underlie these symptoms include disruptions to the immune and endocrine systems. Recently circadian rhythm disruption has emerged as a related pathophysiological mechanism underlying cancer- and cancer-treatment related symptoms. Circadian rhythms are endogenous biobehavioral cycles lasting approximately 24 hours in humans and generated by the circadian master clock – the hypothalamic suprachiasmatic nucleus. The suprachiasmatic nucleus orchestrates rhythmicity in a wide range of bodily functions including hormone levels, body temperature, immune response, and rest-activity behaviors. In this review, we describe four common approaches to the measurement of circadian rhythms, highlight key research findings on the presence of circadian disruption in cancer patients, and provide a review of the literature on associations between circadian rhythm disruption and cancer- and treatment-related symptoms. Implications for future research and interventions will be discussed.en
dc.description.versionPeer revieweden
dc.format.extent1878435
dc.format.extent
dc.identifier.citationAmidi, A & Wu, L M 2022, 'Circadian disruption and cancer- and treatment-related symptoms', Frontiers in Oncology, vol. 12, 1009064. https://doi.org/10.3389/fonc.2022.1009064en
dc.identifier.doi10.3389/fonc.2022.1009064
dc.identifier.issn2234-943X
dc.identifier.other251176218
dc.identifier.other4544dce1-53c0-4ccd-b511-317794afeb7d
dc.identifier.otherORCID: /0000-0003-2241-9905/work/174438964
dc.identifier.other85142003099
dc.identifier.other36387255
dc.identifier.urihttps://hdl.handle.net/20.500.11815/8598
dc.language.isoen
dc.relation.ispartofseriesFrontiers in Oncology; 12()en
dc.relation.urlhttps://pure.au.dk/portal/en/publications/f29a4117-a7a2-4dd5-9a32-089418b974dfen
dc.rightsinfo:eu-repo/semantics/openAccessen
dc.titleCircadian disruption and cancer- and treatment-related symptomsen
dc.type/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/articleen

Skrár

Original bundle

Niðurstöður 1 - 1 af 1
Nafn:
fonc-12-1009064.pdf
Stærð:
1.79 MB
Snið:
Adobe Portable Document Format